Biologic treatments in Behçet’s disease
Open Access
- 22 November 2021
- journal article
- review article
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 8 (4), 217-222
- https://doi.org/10.5152/eurjrheum.2020.20138
Abstract
Behçet’s disease,treatment,biologic agentsKeywords
This publication has 117 references indexed in Scilit:
- Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behçet diseaseProceedings of the National Academy of Sciences of the United States of America, 2013
- Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical TrialsOphthalmology, 2013
- Expression of regulatory receptors on γδ T Cells and their cytokine production in Behcet's diseaseArthritis Research & Therapy, 2013
- Critical role of IL-21 in modulating TH17 and regulatory T cells in Behçet diseaseJournal of Allergy and Clinical Immunology, 2011
- Anti-TNF Agents for Behçet's Disease: Analysis of Published Data on 369 PatientsSeminars in Arthritis and Rheumatism, 2011
- A putative functional variant within the UBAC2 gene is associated with increased risk of Behçet's diseaseArthritis & Rheumatism, 2011
- Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's diseaseNature Genetics, 2010
- Identification of novel genetic susceptibility loci for Behçet's disease using a genome-wide association studyArthritis Research & Therapy, 2009
- A Double-masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's DiseaseOcular Immunology and Inflammation, 2007
- Behçet's DiseaseThe New England Journal of Medicine, 1999